Assay panels for multiprotein systems targeted by oncology therapeutics, including immune checkpoints and related immune regulators, growth factor receptor/kinase systems, cell cycle regulators, cell death regulators, hormone receptor systems, and antibody drug conjugate (ADC) targets.
Precise abundance measurement of editing nucleases and key host system proteins in tissues that govern both successful editing, as well as off-target effects and toxicity. This information informs dosing strategy to maximize efficacy.
Assay panels to quantify therapeutic target abundance, along with immune cell infiltration and key protein mediators of tissue integrity and injury.
Routinely achieve measurements over 2-3 orders of magnitude in protein abundance. In addition, Target Sufficiency® can simultaneously verify the presence of critical host proteins, such as ubiquitin E3 ligase proteins to which PROTACS and similar molecules are targeted. Target Sufficiency™ can survey cell and tissue models for preclinical development of drug candidates and prioritize tumor types for therapeutic programs.